BillionToOne, Inc. Class A Common Stock
Veridion Score
Composite trend over time
Why is BLLN moving today?
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for BLLN.
BLLN insider activity
BillionToOne, Inc. Class A Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for BLLN.
BLLN contract awards, year to date.
Public federal awards linked to this ticker.
BLLN lobbying filings, year to date.
Registered lobbying filings matched to BillionToOne, Inc. Class A Common Stock.